N	Concordance
1	get in approaches to passive and active immunotherapy of colorectal cancer. The 
2	randomized controlled study of adjuvant immunotherapy combined with chemotherapy
3	VHD. The use of NK cells as an adoptive immunotherapy after BMT is attractive fo
4	up to about 80%.  The effect of allergy immunotherapy should last many years, if
5	s are necessary for prolonged antitumor immunotherapy. In addition, the data sug
6	2 patients were treated with IL-2-based immunotherapy. Two induction treatment c
7	oma cells for use as vaccines in cancer immunotherapy, we evaluated three IL-12 
8	. HER2/neu is an appropriate target for immunotherapy due to the high level of e
9	  This study aimed to investigate local immunotherapy with Nocardia rubra cell w
10	 the design of adoptive T-cell-mediated immunotherapy trials for the treatment o
11	on and that the design of CDR3-specific immunotherapy would be possible using th
12	ted during the traditional subcutaneous immunotherapy. Some studies carried out 
13	 is correlated to a lack of response to immunotherapy in several malignancies, s
14	nts were re-stung while receiving venom immunotherapy: only one had a mild syste